TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26547662

Group type: EXPERIMENTAL
Intervention: Current use of sulfonylureas
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Current use of metformin
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Past use of sulfonylureas
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Past use of metformin
Number of subjects: 443
Study: 24160184

Group type: EXPERIMENTAL
Intervention: Teacher professional development (6 days) aimed at improving expressive and receptive oral language skills and early literacy; included school-based continuing contact and completion of a postgraduate unit on early language and literacy.
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Standard teaching according to state auspiced curriculum guidelines (control arm).
Number of subjects: 1254
Study: 22677258

Group type: EXPERIMENTAL
Intervention: CAD106 50 μg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CAD106 150 μg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CAD106 (both dosages)
Number of subjects: 58
Study: 21125811

Group type: EXPERIMENTAL
Intervention: Chlortalidone (12.5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trichlormethiazide (1 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlortalidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 40
Study: 17935533

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relationship enhancement program
Number of subjects: 0
Study: 15802115

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (counseling on stopping smoking, low-calorie diet, physical exercise)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Customary treatments (control group)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 436
Study: 16882959

Group type: EXPERIMENTAL
Intervention: Face-to-face interview with a health care provider (physician or nurse)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Written self-completed questionnaire (WAST)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Computer-based self-completed questionnaire
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Written format (WAST)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Partner Violence Screen (PVS)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Woman Abuse Screening Tool (WAST)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Written WAST vs other combinations
Number of subjects: 2602
Study: 11763911

Group type: EXPERIMENTAL
Intervention: Essential oil-containing dentifrice (EO)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control dentifrice (without essential oils)
Number of subjects: 321
Study: 8840945

Group type: EXPERIMENTAL
Intervention: Nystatin tablets 500,000 units four times a day
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (no nystatin)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 397
Study: 1515389

Group type: EXPERIMENTAL
Intervention: Retrobulbar block
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Younger patients (less than 65 years)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 300
Study: 6434423

Group type: EXPERIMENTAL
Intervention: Essential amino acids infusion (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined essential and non-essential amino acids infusion (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine laboratory data and protein metabolism parameters (both groups)
Number of subjects: 0
Study: 30305345

Group type: EXPERIMENTAL
Intervention: Gla‐300 (0.35 ± 0.08 units · kg‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 18
Study: 29154168

Group type: EXPERIMENTAL
Intervention: Psychotherapy plus a web‐based depression program ("deprexis")
Number of subjects: 98

Group type: COMPARATOR
Intervention: Regular psychotherapy
Number of subjects: 98
Study: 27750364

Group type: EXPERIMENTAL
Intervention: Pneumatic unloader brace and conventional treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 36
Study: 24417765

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Normal P-wave duration
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall (aIAB presence)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Drug used for cardioversion (Propafenone vs Vernakalant)
Number of subjects: 61
Study: 22822190

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Simulation training after second session
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control training after second session
Number of subjects: 61
Study: 19997723

Group type: EXPERIMENTAL
Intervention: High diuresis (Group D) - pressure infusion of approximately 1 L of Ringer acetate solution and 20 mg of furosemide during a 30-40 min treatment session.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal diuresis (Group 0) - no bladder catheter.
Number of subjects: 125
Study: 19012818

Group type: EXPERIMENTAL
Intervention: 30 mg/day lisdexamfetamine
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 50 mg/day lisdexamfetamine
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 70 mg/day lisdexamfetamine
Number of subjects: 420

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 420
Study: 15867832

Group type: EXPERIMENTAL
Intervention: Asthma education program (Open Airways) followed by 5 monthly visits with a nurse practitioner
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 12790313

Group type: EXPERIMENTAL
Intervention: Evidence-based (EB) booklet
Number of subjects: 214

Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 214
Study: 10649933

Group type: COMPARATOR
Intervention: Compoglass (C)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fuji II LC (F)
Number of subjects: 31
Study: 8907141

Group type: EXPERIMENTAL
Intervention: Positive intrasurgical suggestion directed towards reducing pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving information about pain without suggestion content
Number of subjects: 0
Study: 2063854

Group type: EXPERIMENTAL
Intervention: Erythropoietin (50 U/kg IV three times a week, increased by 25 U/kg every 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythropoietin (150 to 300 U/kg/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 20
Study: 30879077

Group type: EXPERIMENTAL
Intervention: 'overload' message with 2/2 threat‐to‐efficacy ratio
Number of subjects: 242

Group type: COMPARATOR
Intervention: 'standard' message with 1/1 threat‐to‐efficacy ratio
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: High efficacy information
Number of subjects: 242
Study: 31547503

Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich antioxidant juice (AJ), dosage: 240 mL twice-a-day for nine days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA), dosage: 240 mL twice-a-day for nine days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich antioxidant juice (AJ)
Number of subjects: 30
Study: 28762617

Group type: EXPERIMENTAL
Intervention: Extended full-dose betrixaban (80 mg once daily)
Number of subjects: 28227

Group type: COMPARATOR
Intervention: Standard-duration enoxaparin
Number of subjects: 28227

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 28227

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 28227

Group type: COMPARATOR
Intervention: Reduced-dose betrixaban
Number of subjects: 28227
Study: 25357120

Group type: EXPERIMENTAL
Intervention: Exercise trial (40 × 6 s maximal cycle sprints)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (inactive)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise trial
Number of subjects: 9
Study: 23838844

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 0
Study: 21268098

Group type: EXPERIMENTAL
Intervention: Rectal distension (150 ml of normal saline)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rectum undistended
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rectal distension
Number of subjects: 30
Study: 19116960

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 16545434

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 34
Study: 15848978

Group type: EXPERIMENTAL
Intervention: Antibacterial chlorhexidine/thymol-containing varnish
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 32
Study: 11561502

Group type: EXPERIMENTAL
Intervention: Cold compression dressing (Cryo/Cuff, Aircast, UK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified Robert Jones bandage
Number of subjects: 60
Study: 9782139

Group type: EXPERIMENTAL
Intervention: Preoperative administration of two injections of a depot formulation of leuprolide acetate 28 days apart
Number of subjects: 67

Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 67
Study: 8164940

Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 4 weeks
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 6 weeks
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 8 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Repeat smear done 3 months after postpartum examination
Number of subjects: 184
Study: 3059587

Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slo-bid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Slo-Phyllin Gyrocaps (reference)
Number of subjects: 14
Study: 31295916

Group type: EXPERIMENTAL
Intervention: Maternal lipid‐based nutrient supplement (LNS)
Number of subjects: 966
Study: 27408987

Group type: EXPERIMENTAL
Intervention: Mushroom blend containing Cordyceps militaris (4 g·d‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Maltodextrin (PL)
Number of subjects: 28
Study: 26009024

Group type: EXPERIMENTAL
Intervention: Discontinuation of cotrimoxazole (CTX) prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of cotrimoxazole (CTX) prophylaxis
Number of subjects: 0
Study: 23482526

Group type: EXPERIMENTAL
Intervention: VenaSeal™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Covidien ClosureFast™
Number of subjects: 0
Study: 21298654

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Atorvastatin 5 mg/ezetimibe 5 mg
Number of subjects: 82
Study: 19026531

Group type: COMPARATOR
Intervention: General anesthesia (thiopental 4 mg/kg, succinylcholine 1-1.5 mg/kg, 1% end-tidal concentration of sevoflurane in nitrous oxide and 50% oxygen)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Neuraxial anesthesia (intrathecal 0.5% levobupivacaine 1.8-2.2 mL and epidural fentanyl 1 microg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Neuraxial anesthesia
Number of subjects: 35
Study: 16883221

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg b.i.d for 90 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no gemfibrozil)
Number of subjects: 44
Study: 15536776

Group type: EXPERIMENTAL
Intervention: Disulfiram (1500 mg weekly in divided doses)
Number of subjects: 46
Study: 11421840

Group type: EXPERIMENTAL
Intervention: 75 mg/ml (7.5%) hypertonic saline (HS) administered at 1.6 ml/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: 9 mg/ml normal saline administered at 13 ml/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 75 mg/ml (7.5%) hypertonic saline (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 9 mg/ml normal saline
Number of subjects: 40
Study: 9010482

Group type: EXPERIMENTAL
Intervention: Whole resting saliva
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whole saliva during chewing-stimulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Resting saliva
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Parotid saliva with increased secretion rates
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Parotid saliva over time with increased secretion rates
Number of subjects: 8
Study: 8515969

Group type: EXPERIMENTAL
Intervention: Lenses with varying back optic zone radius (BOZR) from 8.20 to 9.00 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monocurve lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bicurve and aspheric lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenses with edge thickness varying from 0.12 to 0.24 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plus power lenses (+1.00 to -6.00 D)
Number of subjects: 20
Study: 2894715

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (I/C group)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cefotaxime combined with metronidazole and cloxacillin (CX/M/CL group)
Number of subjects: 143
Study: 30528419

Group type: EXPERIMENTAL
Intervention: Combined cholesterol-lowering nutraceutical containing artichoke dry extract and berberine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized control diet
Number of subjects: 0
Study: 28449590

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom™ G4 Platinum CGM System®
Number of subjects: 116

Group type: COMPARATOR
Intervention: Self-monitoring blood glucose (SMBG)
Number of subjects: 116
Study: 25629793

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide and isotonic nasal saline for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic nasal saline for 2 weeks
Number of subjects: 60
Study: 23522927

Group type: EXPERIMENTAL
Intervention: Pain Self-Management (PSM) program
Number of subjects: 141

Group type: COMPARATOR
Intervention: Exercise-Attention Control (EAC) group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waiting List (WL) group
Number of subjects: 141
Study: 20716319

Group type: EXPERIMENTAL
Intervention: Synbiotics (90% short‐chain galacto‐oligosaccharides, 10% long‐chain fructo‐oligosaccharides: Immunofortis(®) and Bifidobacterium breve M‐16V)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 19807821

Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (OFD and GTR)
Number of subjects: 16
Study: 16977442

Group type: EXPERIMENTAL
Intervention: 80 ml contrast material at 2.0 ml/s
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 80 ml contrast material followed by 40 ml saline at 2.0 ml/s
Number of subjects: 120

Group type: COMPARATOR
Intervention: 60 ml contrast material at 1.5 ml/s
Number of subjects: 120

Group type: COMPARATOR
Intervention: 60 ml contrast material followed by 30 ml saline at 1.5 ml/s
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Saline chaser (40 ml or 30 ml)
Number of subjects: 120
Study: 15074087

Group type: EXPERIMENTAL
Intervention: Xuesaitong injection (XSTI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 87
Study: 11190987

Group type: EXPERIMENTAL
Intervention: Choline chloride (2 g) added to usual TPN regimen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual TPN regimen (Control)
Number of subjects: 11
Study: 9613534

Group type: EXPERIMENTAL
Intervention: 20 mL 0.9% saline injected into the epidural catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 mL 0.9% saline injected into the epidural catheter
Number of subjects: 20
Study: 8578840

Group type: EXPERIMENTAL
Intervention: Hib vaccine mixed with whole‐cell DTP vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hib vaccine administered in separate limbs from whole‐cell DTP vaccine
Number of subjects: 0
Study: 2517007

Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) 1 mg every morning or 1 mg twice daily if necessary
Number of subjects: 157

Group type: COMPARATOR
Intervention: Methyldopa (MD) 250 mg morning and evening or 500 mg twice daily if necessary
Number of subjects: 157
Study: 326378

Group type: EXPERIMENTAL
Intervention: Periodic screening with clinical examination and mammography
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Screening under 50 years of age
Number of subjects: 128
Study: 29602709

Group type: EXPERIMENTAL
Intervention: Adhesive fixation device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suture fixation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Staff recommendation
Number of subjects: 100
Study: 27684085

Group type: EXPERIMENTAL
Intervention: 4 mL LMWF-5A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control (saline)
Number of subjects: 40
Study: 26849537

Group type: EXPERIMENTAL
Intervention: Exergames (EG) using the Xbox Kinect™ device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 100
Study: 23221493

Group type: EXPERIMENTAL
Intervention: Comments to the 'Black' magazine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comments to the 'White' magazine
Number of subjects: 32
Study: 21212502

Group type: EXPERIMENTAL
Intervention: Pitching from a mound
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Throwing 37 m from flat ground
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Throwing 55 m from flat ground
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maximum-distance throws
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Throwing distance increased
Number of subjects: 17
Study: 18058852

Group type: EXPERIMENTAL
Intervention: Escitalopram (mean dose 26.5 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16494565

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) plus Usual Care
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 48
Study: 12626460

Group type: COMPARATOR
Intervention: RNase L 37-kDa/83-kDa ratio
Number of subjects: 11
Study: 11088083

Group type: EXPERIMENTAL
Intervention: Topical zanamivir (combined inhaled and intranasal zanamivir, inhaled zanamivir)
Number of subjects: 3815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3815

Group type: EXPERIMENTAL
Intervention: Intranasal and inhaled zanamivir
Number of subjects: 3815

Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir
Number of subjects: 3815
Study: 9052309

Group type: EXPERIMENTAL
Intervention: Combined epidural/general anesthesia (Group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inhaled anesthesia (Group II)
Number of subjects: 70
Study: 1586184

Group type: EXPERIMENTAL
Intervention: Caffeine (12.5 mg/kg loading dose and 3 mg/kg daily maintenance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Caffeine (25 mg/kg loading and 6 mg/kg daily maintenance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Theophylline (7.5 mg/kg loading and 3 mg/kg thrice daily maintenance)
Number of subjects: 44
Study: 2417075

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic placement of a permanent biliary endoprosthesis (PTE)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 53
Study: 30214183

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) including recording of symptoms, oxygen saturation, spirometry, and video consultations.
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) for patients with baseline 15D score <0.75
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care (control group) for patients with baseline 15D score <0.75
Number of subjects: 281

Group type: COMPARATOR
Intervention: Telemonitoring (TM) and Usual care (control group)
Number of subjects: 281
Study: 27347622

Group type: EXPERIMENTAL
Intervention: Continuous physical activity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Open sub‐inguinal varicocelectomy (Group 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Loupe‐assisted sub‐inguinal varicocelectomy (Group 2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Microscope‐assisted sub‐inguinal varicocelectomy (Group 3)
Number of subjects: 64
Study: 23909452

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid for 6 months
Number of subjects: 101
Study: 23715201

Group type: EXPERIMENTAL
Intervention: ozonated olive oil and mineral wash
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: placebo olive oil and mineral wash
Number of subjects: 51

Group type: COMPARATOR
Intervention: ozonated olive oil
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo olive oil only
Number of subjects: 51
Study: 21168874

Group type: EXPERIMENTAL
Intervention: Testosterone 150 mg + Dutasteride 0.25 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Testosterone 250 mg + Dutasteride 0.25 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Testosterone 400 mg + Dutasteride 0.25 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Testosterone 400 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dutasteride 0.25 mg
Number of subjects: 43
Study: 18346506

Group type: EXPERIMENTAL
Intervention: Preterm male subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Term male subjects
Number of subjects: 29
Study: 17079759

Group type: EXPERIMENTAL
Intervention: Epirubicin plus CMF
Number of subjects: 2391

Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 2391
Study: 14566298

Group type: EXPERIMENTAL
Intervention: Newer Doppler diastolic function parameters
Number of subjects: 1012